Presentation is loading. Please wait.

Presentation is loading. Please wait.

BIRC6 is expressed in the tumorigenic Aldefluorhigh fraction of colonosphere cells. BIRC6 is expressed in the tumorigenic Aldefluorhigh fraction of colonosphere.

Published byPeter Fowler Modified over 5 years ago

Similar presentations

Presentation on theme: "BIRC6 is expressed in the tumorigenic Aldefluorhigh fraction of colonosphere cells. BIRC6 is expressed in the tumorigenic Aldefluorhigh fraction of colonosphere."— Presentation transcript:

1 BIRC6 is expressed in the tumorigenic Aldefluorhigh fraction of colonosphere cells.
BIRC6 is expressed in the tumorigenic Aldefluorhigh fraction of colonosphere cells.A, Western blot analysis of BIRC6 levels in colonospheres and differentiated tumor cells in all pairs. B, Single cell cultures of L145 colonospheres were separated into Aldefluor®high and Aldefluor®low cell populations by FACS sorting. C, Western blot analysis of Aldefluor®high and Aldefluor®low cell populations for expression of BIRC6. WJ Van Houdt et al. Mol Cell Proteomics 2011;10:M © 2011 by The American Society for Biochemistry and Molecular Biology, Inc.

Download ppt "BIRC6 is expressed in the tumorigenic Aldefluorhigh fraction of colonosphere cells. BIRC6 is expressed in the tumorigenic Aldefluorhigh fraction of colonosphere."

Similar presentations

T3 increased J7-TRα1 cell migration and proliferation both in vitro and in vivo. T3 increased J7-TRα1 cell migration and proliferation both in vitro and.

T3 increased J7-TRα1 cell migration and proliferation both in vitro and in vivo. T3 increased J7-TRα1 cell migration and proliferation both in vitro and.
Correlation of log-transformed signal intensity from two Affymetrix microarray hybridizations using platelet RNA. Plotted are those probesets with an average.

Correlation of log-transformed signal intensity from two Affymetrix microarray hybridizations using platelet RNA. Plotted are those probesets with an average.
Sequence alignment of C-terminal phosphorylated plant aquaporins

Sequence alignment of C-terminal phosphorylated plant aquaporins
Distribution of phosphorylation sites identified in the cytosolic phosphoproteome.A, numbers of approved phosphopeptides, previously phosphorylated peptides,

Distribution of phosphorylation sites identified in the cytosolic phosphoproteome.A, numbers of approved phosphopeptides, previously phosphorylated peptides,
Microvesicles released by PC-3 cells.

Microvesicles released by PC-3 cells.
A quantitative proteomics strategy to identify SUMO-conjugated proteins. A quantitative proteomics strategy to identify SUMO-conjugated proteins. HeLa.

A quantitative proteomics strategy to identify SUMO-conjugated proteins. A quantitative proteomics strategy to identify SUMO-conjugated proteins. HeLa.
Expression of retinitis pigmentosa protein RP1 in human bronchial epithelial cells. Expression of retinitis pigmentosa protein RP1 in human bronchial epithelial.

Expression of retinitis pigmentosa protein RP1 in human bronchial epithelial cells. Expression of retinitis pigmentosa protein RP1 in human bronchial epithelial.
Percentage of proteins identified in envelope membrane extracts according to the purification method and the number of transmembrane domains. Percentage.

Percentage of proteins identified in envelope membrane extracts according to the purification method and the number of transmembrane domains. Percentage.
Illustration of matched (FL-IFN-γR2/GFP and IFN-γR1/EBFP) and mismatched (IFN-γR1/EBFP and FL-IL-10R2/GFP) pairs of receptors. Illustration of matched.

Illustration of matched (FL-IFN-γR2/GFP and IFN-γR1/EBFP) and mismatched (IFN-γR1/EBFP and FL-IL-10R2/GFP) pairs of receptors. Illustration of matched.
Frequency distribution of the GRAVY of the theoretical proteins (open bars) and of 110 genes encoding proteins identified on a 2-D electrophoresis gel,

Frequency distribution of the GRAVY of the theoretical proteins (open bars) and of 110 genes encoding proteins identified on a 2-D electrophoresis gel,
Improvement of insulin sensitivity by treatment of the annexin A1 receptor agonist in HFD mice. Improvement of insulin sensitivity by treatment of the.

Improvement of insulin sensitivity by treatment of the annexin A1 receptor agonist in HFD mice. Improvement of insulin sensitivity by treatment of the.
Time course of phosphorylation changes at Ser-293, Ser-300, and Ser-232 in PDHE1α following kinase inhibition with DCA. A, relative quantitation over three.

Time course of phosphorylation changes at Ser-293, Ser-300, and Ser-232 in PDHE1α following kinase inhibition with DCA. A, relative quantitation over three.
Two-dimensional electrophoresis results and validation with Western blotting. Two-dimensional electrophoresis results and validation with Western blotting.

Two-dimensional electrophoresis results and validation with Western blotting. Two-dimensional electrophoresis results and validation with Western blotting.
Significantly enriched phosphorylation motifs from up-regulated phosphopeptides by Motif-X analysis. Significantly enriched phosphorylation motifs from.

Significantly enriched phosphorylation motifs from up-regulated phosphopeptides by Motif-X analysis. Significantly enriched phosphorylation motifs from.
Visual validation of the computational outputs.

Visual validation of the computational outputs.
Assay of NOS activity. Assay of NOS activity. Box show total NOS activity, the calcium-dependent activity of the constitutive isoforms of NOS (eNOS and.

Assay of NOS activity. Assay of NOS activity. Box show total NOS activity, the calcium-dependent activity of the constitutive isoforms of NOS (eNOS and.
Workflow of the integrated proteomics approach to identify the abnormal network in NF1-KD PC12 cells. Workflow of the integrated proteomics approach to.

Workflow of the integrated proteomics approach to identify the abnormal network in NF1-KD PC12 cells. Workflow of the integrated proteomics approach to.
Experimental setup.A, topology models of the overexpressed membrane protein GFP fusions. Experimental setup.A, topology models of the overexpressed membrane.

Experimental setup.A, topology models of the overexpressed membrane protein GFP fusions. Experimental setup.A, topology models of the overexpressed membrane.
Representative example of LAXIC performance for complex plant phosphoproteome. Representative example of LAXIC performance for complex plant phosphoproteome.A.

Representative example of LAXIC performance for complex plant phosphoproteome. Representative example of LAXIC performance for complex plant phosphoproteome.A.
Success rates in validation of antibodies from external providers

Success rates in validation of antibodies from external providers

Similar presentations

Ads by Google